| Intervention | Coverage | Initial efficacy | Half-life or duration (years) | Decay type |
---|---|---|---|---|---|
 | Preventing infection | ||||
Simulated malaria intervention properties | Anti-infective vaccine | 0–1 | 0.3–0.95 | 0.5–5 | Weibull (k = 0.8) (Sigmoidal) |
 | Anti-infective monoclonal antibody | 0–1 | 0.3–0.95 | 0.167–0.667 | Weibull (k = 3) (Biphasic) |
 | Blood stage clearance | ||||
 | Antimalarial drugs | 0–1 | 0.8–1 | 0–0.1667 | Exponential |
 | Transmission blocking | ||||
 | Vaccine | 0–1 | 0.3–0.95 | 0.5–5 | Weibull (k = 0.8) (Biphasic) |
 | Preprandial killing effect (affects indoor mosquito biting) | ||||
 | Eave tubes | 0–1 | 0.3–0.99 | 0.5–5 | Weibull (k = 3) (Sigmoidal) |
 | Preprandial and postprandial killing effect (affects outdoor mosquito biting) | ||||
 | Attractive targeted sugar baits | 0–1 | 0.7–0.99 | 0.167–0.667 | Step |
Simulated malaria transmission settings | EIR range: 1–25, representing a PfPR0–99 of 13–88% and a PfPR2–10 of 7.2–74.0% | ||||
Case management (baseline scenario) range: 0–0.8, corresponding to a probability range of seeking care within 5 days from the onset of fever of 0–0.5 Seasonality levels 1. High seasonal setting with one transmission peak over a year 2. Perennial setting with constant yearly transmission | |||||
Proportion of indoor-biting mosquitoes, out of total indoor and outdoor biting mosquitoes: 3. High (0.8) 4. Medium (0.5) 5. Low (0.2) |